Loading...
Bilateral Trade Intelligence · $99.7K Total Trade · 8 Foreign Suppliers · 4 Indian Buyers · DGFT Verified · Updated March 2026
India imported $99.7K worth of pharmaceutical formulations from Lithuania across 16 verified shipments, from 8 foreign suppliers to 4 Indian buyers. The top suppliers are MS E-PHARM LIMITED ($48.1K) and M/S E-PHARMA LIMITED ($38.8K). The leading products are Doxorubicin ($87K) and Paracetamol ($4K). Average shipment value: $6.2K.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Doxorubicin | $86.9K | 87.2% |
| 2 | Paracetamol | $4.2K | 4.2% |
| 3 | Vaccine | $2.5K | 2.5% |
| 4 | Plasma | $2.1K | 2.1% |
| 5 | Amoxicillin | $1.4K | 1.4% |
| 6 | Potassium | $1.4K | 1.4% |
| 7 | Protein | $1.2K | 1.2% |
India imports 7+ pharmaceutical formulations from Lithuania with a combined trade value of $99.7K. Key products include Doxorubicin ($87K), Paracetamol ($4K), Vaccine ($3K), Plasma ($2K), Amoxicillin ($1K). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 16 verified Indian Customs (DGFT) shipment records.
India exported pharmaceuticals worth $99.7K to Lithuania across 16 verified shipments.
1. MS E-PHARM LIMITED — $48.1K. 2. M/S E-PHARMA LIMITED — $38.8K. 3. LIFE TECHNOLOGIES HOLDINGS PTE LTD — $4.4K. Total: 8 suppliers.
1. SUN PHARMACEUTICAL INDUSTRIES LIMITED — $87.0K. 2. INVITROGEN BIOSERVICES INDIA PRIVATE LIMITED — $5.8K. 3. FRESENIUS KABI ONCOLOGY LIMITED — $4.1K. 4 buyers total.
1. Doxorubicin ($86.9K, 87.2%); 2. Paracetamol ($4.2K, 4.2%); 3. Vaccine ($2.5K, 2.5%); 4. Plasma ($2.1K, 2.1%); 5. Amoxicillin ($1.4K, 1.4%)
Export: . Import: .
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $99.7K corridor reflects quality compliance and pricing advantages.
These are the top pharmaceutical products exported from India to Lithuania, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Lithuania buyers, regulatory requirements, and logistics for that specific product corridor. Products include Doxorubicin ($87K), Paracetamol ($4K), Vaccine ($3K), Plasma ($2K), Amoxicillin ($1K) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
8 Indian pharmaceutical companies export finished formulations to Lithuania. Leading exporters include Ms E-pharm Limited, M/s E-pharma Limited, Life Technologies Holdings Pte Ltd, New Life Biopharma Limited. The top exporter accounts for 48.2% of total India–Lithuania pharma exports. Source: Indian Customs (DGFT).
4 companies in Lithuania import pharmaceutical formulations from India. Top buyers include Sun Pharmaceutical Industries Limited, Invitrogen Bioservices India Private Limited, Fresenius Kabi Oncology Limited, Kopran Limited. The largest buyer accounts for 87.3% of India–Lithuania pharma imports. Source: Indian Customs (DGFT).
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$6.2K per consignment across 16 shipments.
8 Indian companies. Largest: MS E-PHARM LIMITED with $48.1K.
TransData Nexus covers 8 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 16 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
8 Exporters
4 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists